Comparative Pharmacology
Head-to-head clinical analysis: CITANEST FORTE DENTAL versus CITANEST PLAIN DENTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CITANEST FORTE DENTAL versus CITANEST PLAIN DENTAL.
CITANEST FORTE DENTAL vs CITANEST PLAIN DENTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Citanest Forte Dental (prilocaine and epinephrine) acts by blocking sodium channels in nerve cell membranes, inhibiting nerve impulse propagation and producing local anesthesia. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing vascular uptake.
Propylocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by binding to voltage-gated sodium channels, thereby inhibiting sodium influx and blocking conduction of nerve impulses.
1.7 mL (30 mg) of 4% solution for infiltration; 0.5-1.5 mg/kg for nerve block, not to exceed 2.5 mg/kg (maximum 150 mg). Administered submucosally or perineurally.
Adult dose for dental anesthesia: 20-50 mg (0.5-1.25 mL of 4% solution) by infiltration; up to 200 mg (5 mL) by nerve block. Maximum dose: 6 mg/kg, not exceeding 300 mg per appointment.
None Documented
None Documented
Terminal elimination half-life is 1.6–2.0 hours in adults, prolonged in hepatic impairment or neonates.
Terminal elimination half-life is approximately 1.6 hours (range 1–2 hours). This short half-life allows for rapid clearance, minimizing systemic accumulation during repeated dosing in dental procedures.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 95% of elimination, with less than 2% excreted in bile/feces.
Renal excretion of metabolites (primarily 4-hydroxyprilocaine and N-propylalanine) accounts for >95% of elimination; <5% excreted unchanged in urine. Less than 1% eliminated via feces.
Category C
Category C
Local Anesthetic (Dental)
Local Anesthetic (Dental)